A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors.
Ku G, Shen L, Dayyani F, Kratz J, Liang X, Liu F, Wang Z, Feller L, Girda E, Pan H, Kim S, Deng Y, Deng T, Liu T, Powderly J, Spencer K, Schneider R, Berlin J, Xu CC, Ahlers CM, Liu X, Chung JK, Sabbatini P, Park J, Lim Y, Jeon J, Meng Y, Klempner SJ.
Ku G, et al. Among authors: liu t.
Clin Cancer Res. 2025 Jun 30. doi: 10.1158/1078-0432.CCR-24-4280. Online ahead of print.
Clin Cancer Res. 2025.
PMID: 40586719